Dade launches thrombin activity test for research use:
This article was originally published in Clinica
Executive Summary
Dade Behring believes it has moved a step closer to providing physicians with a new assay that could allow doctors to better assess thrombotic and bleeding risk. The Deerfield, Illinois firm has made available for research studies, its endogenous thrombin potential (ETP) test for measuring thrombin activity. The assay is based on the assumption that thrombin generation in plasma or whole blood reflects the sum of the activities and concentrations of procoagulant and anticoagulant substances, said the company. "ETP has the potential to become a standard parameter in coagulation, and we are confident that the research studies will provide the necessary information to bring the assay to full commercialisation," added Jim Reid-Anderson, Dade's chairman, president and CEO.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.